FDA Updates Plavix Label, Leaves Effient With Clear Advantage

FDA's latest revision of labeling for Bristol-Myers Squibb/Sanofi Aventis' Plavix gives Lilly/Daiichi Sankyo a clear-cut advantage to use for its competing antiplatelet agent Effient: Effient can be used with the proton pump inhibitor Prilosec; Plavix cannot